Asunto(s)
Angioplastia Coronaria con Balón/efectos adversos , Disección Aórtica/terapia , Aneurisma Coronario/etiología , Intervención Coronaria Percutánea/efectos adversos , Stents , Disección Aórtica/diagnóstico por imagen , Disección Aórtica/etiología , Aneurisma Coronario/diagnóstico por imagen , Aneurisma Coronario/terapia , Angiografía Coronaria , Femenino , Humanos , Enfermedad Iatrogénica , Masculino , Persona de Mediana EdadAsunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Aneurisma Coronario/etiología , Angioplastia Coronaria con Balón/efectos adversos , Stents , Intervención Coronaria Percutánea/efectos adversos , Disección Aórtica/terapia , Aneurisma Coronario/terapia , Aneurisma Coronario/diagnóstico por imagen , Angiografía Coronaria , Enfermedad Iatrogénica , Disección Aórtica/etiología , Disección Aórtica/diagnóstico por imagenRESUMEN
AbstractPulmonary hypertension is a devastating and refractory disease and there is no cure for this disease. Recently, microRNAs and mesenchymal stem cells emerged as novel methods to treat pulmonary hypertension. More than 20 kinds of microRNAs may participate in the process of pulmonary hypertension. It seems microRNAs or mesenchymal stem cells can ameliorate some symptoms of pulmonary hypertension in animals and even improve heart and lung function during pulmonary hypertension. Nevertheless, the relationship between mesenchymal stem cells, microRNAs and pulmonary hypertension is not clear. And the mechanisms underlying their function still need to be investigated. In this study we review the recent findings in mesenchymal stem cells - and microRNAs-based pulmonary hypertension treatment, focusing on the potential role of microRNAs regulated mesenchymal stem cells in pulmonary hypertension and the role of exosomes between mesenchymal stem cells and pulmonary hypertension.
ResumoA hipertensão pulmonar é uma doença devastadora e refratária, para a qual não existe cura. Recentemente, microRNAs e células-tronco mesenquimais emergiram como novos métodos para tratar a hipertensão pulmonar. Mais de 20 tipos de microRNAs podem participar no processo de hipertensão pulmonar. Ao que parece, microRNAs ou células-tronco mesenquimais podem atenuar alguns sintomas de hipertensão pulmonar em animais de e até mesmo melhorar a função cardíaca e do pulmão durante a hipertensão pulmonar. No entanto, a relação entre células-tronco mesenquimais, microRNAs e hipertensão pulmonar não é clara. E os mecanismos subjacentes a sua função ainda precisam ser investigados. Neste estudo, revisamos as descobertas recentes no tratamento da hipertensão pulmonar baseado em células-tronco mesenquimais e microRNAs, enfocando o papel potencial dos microRNAs para regular as células-tronco mesenquimais na hipertensão pulmonar e o papel dos exossomos entre células-tronco mesenquimais e hipertensão pulmonar.
Asunto(s)
Animales , Humanos , Hipertensión Pulmonar/terapia , Trasplante de Células Madre Mesenquimatosas/métodos , Células Madre Mesenquimatosas/fisiología , MicroARNs/uso terapéutico , Exosomas/fisiología , Hipertensión Pulmonar/fisiopatología , Pulmón/fisiopatologíaRESUMEN
Pulmonary hypertension is a devastating and refractory disease and there is no cure for this disease. Recently, microRNAs and mesenchymal stem cells emerged as novel methods to treat pulmonary hypertension. More than 20 kinds of microRNAs may participate in the process of pulmonary hypertension. It seems microRNAs or mesenchymal stem cells can ameliorate some symptoms of pulmonary hypertension in animals and even improve heart and lung function during pulmonary hypertension. Nevertheless, the relationship between mesenchymal stem cells, microRNAs and pulmonary hypertension is not clear. And the mechanisms underlying their function still need to be investigated. In this study we review the recent findings in mesenchymal stem cells - and microRNAs-based pulmonary hypertension treatment, focusing on the potential role of microRNAs regulated mesenchymal stem cells in pulmonary hypertension and the role of exosomes between mesenchymal stem cells and pulmonary hypertension.